Antonella Palazzo

Università Cattolica del Sacro Cuore — Italy

Biochemistry, Genetics and Molecular Biology · Life Sciences

20h-index1.8kcitations128works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(33), Advanced Breast Cancer Therapies(22), Cancer Treatment and Pharmacology(20), HER2/EGFR in Cancer Research(18), Breast Lesions and Carcinomas(11)

Publications124 total

Pregnancy vs. Postpartum Breast Cancer: Distinct Tumor Biology and Survival Trends in a Contemporary Cohort
Cancers·2025· 1 citedOpen Access
Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer
npj Breast Cancer·2025· 1 citedOpen Access
Digital integration of narrative medicine and patient-reported outcome measures to improve understanding of quality of life in metastatic breast cancer: the PERGIQUAL study
The Oncologist·2025Open Access
Lifestyle and environmental factors in women carrying <i>BRCA</i> pathogenic variants with and without cancer
JNCI Cancer Spectrum·2025Open Access
Comparison of machine learning and deep learning models for survival prediction in early-stage hormone receptor-positive/HER2-negative breast cancer receiving neoadjuvant chemotherapy
ESMO Real World Data and Digital Oncology·2025· 1 citedOpen Access
576P Simultaneous integrated boost (sib) intensity-modulated radiotherapy for treatment of bone metastases: Late analysis of a breast cancer cohort
Annals of Oncology·2025
516P Gradient boosting machine (GBM) for predicting progression-free survival (PFS) in hormone-receptor positive (HR+) metastatic breast cancer (mBC) receiving upfront CDK4/6 inhibitors (CDK4/6i)
Annals of Oncology·2025
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study
Breast Cancer Research and Treatment·2025
Bone Health and Endocrine Therapy with Ovarian Function Suppression in Premenopausal Early Breast Cancer: A Real-Life Monocenter Experience with Denosumab
Current Oncology·2025Open Access
Long term outcomes of breast primary sarcomas and malignant phyllodes tumors: 20 years observational analysis of the BEAM∗ study group. (∗the breast European association for mesenchymal tumors)
European Journal of Surgical Oncology·2025· 1 citedOpen Access
Predictive risk factors of recurrence in breast cancer after neoadjuvant treatment: the NEORISK study
Future Oncology·2025
Abstract P1-11-18: Detrimental effect on survival of neoadjuvant (NACT) versus adjuvant (ACT) chemotherapy in stage II-III hormone receptor-positive &amp; HER2-neg (HR+/HER2-) breast cancer: A propensity score-matched (PSM) analysis of a retrospective patient series
Clinical Cancer Research·2025
Abstract P1-12-11: Individualized Breast Cancer Treatment Strategies: Real-World Insights from the ROSE Study
Clinical Cancer Research·2025
PARPi effectiveness after CDK4/6i in <i>BRCA1</i> - and <i>BRCA2</i> -associated HR+/HER2- advanced breast cancer: Results from the multicenter real-world PAMBRACA study.
Journal of Clinical Oncology·2025· 1 cited
236P Bone health (BH) and endocrine therapy (ET) in premenopausal early breast cancer (eBC): A real-life monocenter experience with denosumab
ESMO Open·2025Open Access
390P Predictors of outcome with trastuzumab-deruxtecan (T-DXd) in HER2-positive advanced breast cancer (HER2+ aBC): A multicentric, cohort study (DeReal-REST)
ESMO Open·2025Open Access
Malignant Mesenchymal Tumors of the Breast: Current Challenges and New Perspectives on Primary Sarcomas and Malignant Phyllodes Tumors
Life·2025· 3 citedOpen Access
Role of radiomics in predicting early disease recurrence in locally advanced breast cancer patients: integration of radiomic features and RECIST criteria
La radiologia medica·2025· 1 cited
Activity and Efficacy of Neoadjuvant Chemotherapy in Luminal-HER2 Negative Early Breast Cancer According to HER2 Score (Low vs. Score 0): A Retrospective Study
Clinical Breast Cancer·2025· 2 citedOpen Access
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapy
npj Breast Cancer·2025· 8 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Roberto Iacovelli(21), Enrico Cortesi(17), Emilio Bria(13), Armando Orlandi(12), Giampaolo Tortora(12), Giovanna Garufi(10), Alessandra Fabi(9), Ida Paris(7), Luisa Carbognin(7), Gianluca Franceschini(7), Giuseppe Naso(6), Daniele Alesini(6), Patrizia Trenta(6), Marco Colleoni(6), Vincenzo Bagnardi(5), Emilia Montagna(5), Giuseppe Cancello(5), Paola Gazzaniga(4), Emanuela Risi(4), Giovanni Scambia(4)